

Nicholas Weber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/641695/publications.pdf>

Version: 2024-02-01

12
papers

97
citations

1684188
5
h-index

1372567
10
g-index

12
all docs

12
docs citations

12
times ranked

145
citing authors

#	ARTICLE	IF	CITATIONS
1	An Individualized Exercise Intervention for People with Multiple Myeloma—Study Protocol of a Randomized Waitlist-Controlled Trial. <i>Current Oncology</i> , 2022, 29, 901-923.	2.2	2
2	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.8	1
3	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). <i>Blood</i> , 2021, 138, 2728-2728.	1.4	1
4	Tolerability of proactive enteral nutrition post allogeneic haematopoietic progenitor cell transplant: A randomised comparison to standard care. <i>Clinical Nutrition</i> , 2020, 39, 1364-1370.	5.0	18
5	Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome post allogeneic transplantation. <i>British Journal of Haematology</i> , 2020, 188, 570-581.	2.5	37
6	Weekly Cyclophosphamide-Bortezomib-Dexamethasone Induction Performs Comparably to Twice-Weekly Dosing with Respect to Both Response Rates and Survival after Autologous Transplant. <i>Acta Haematologica</i> , 2020, 143, 295-296.	1.4	0
7	Nutrition support during allogeneic stem cell transplantation: evidence versus practice. <i>Supportive Care in Cancer</i> , 2020, 28, 5441-5447.	2.2	15
8	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). <i>Blood</i> , 2020, 136, 4-5.	1.4	1
9	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 503-508.	1.7	8
10	“Real-world” Australian experience of pomalidomide for relapsed and refractory myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1514-1516.	1.3	11
11	Transient immune-mediated agranulocytosis following <i>Mycoplasma pneumoniae</i> infection. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224537.	0.5	2
12	The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015, 90, E145.	4.1	1